



The NASH Education Program™ – Inaugural Press Conference, Paris – March 9, 2017

- › **Inaugural event for the launch of *The NASH Education Program™* endowment fund, Hôtel de Sers (Paris) – March 9, 2017 from 9am to 1pm**
- › **With the participation of the President of its Scientific Committee, Professor Sven Francque, Head of Department, Gastroenterology and Hepatology Antwerp University Hospital, Antwerp, Belgium, as well as Professor Bertrand Cariou, Director of the Thorax Institute (*Institut du Thorax*), Nantes University Hospital, France, also a member of the Scientific Committee**
- › **Presentation of the mission, the objectives, the means, and the first initiatives of the fund engaged or planned for 2017**

Lille (France), Cambridge (Massachusetts, United States), February 14, 2017 – GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that a press conference will be held for the launch of ***The NASH Education Program™***, its endowment fund created at the end of 2016.

The press conference will be the opportunity to present the action plan for the disease awareness activities aimed at disseminating scientific and medical knowledge about NASH, to the medical community, patients, and the general public.

The event will be hosted by ***The NASH Education Program™***'s Scientific Committee President Pr. Sven Francque, MD, PhD, Head of Department, Gastroenterology and Hepatology Antwerp University Hospital, Antwerp, Belgium, and by Pr. Bertrand Cariou, Director of the Thorax Institute (*Institut du Thorax*), Nantes University Hospital, France, also a member of the Scientific Committee.

While most advanced drug-candidates are currently being evaluated in a final clinical trial phase before commercialization in NASH, including GENFIT's lead compound elafibranor, GENFIT is preparing for the future.

The NASH Education Program™'s ambition is indeed to contribute to the global effort aimed at developing disease awareness in relation to public health challenges brought on by the development of NASH, and at increasing knowledge around the disease without waiting for the first diagnostic and therapeutic solutions to be available on the market.

The NASH Education Program™ will design, fund, and support collaborative approaches involving partners from different backgrounds such as academic, corporate, or regulatory, and with



PRESS RELEASE

the potential to create valuable synergies in the NASH space, for the best patient care. Volunteers will also have the opportunity to contribute to various initiatives.

Jean-François Mouney, Chairman & CEO of GENFIT, and President of The NASH Education Program™ commented: *“This event symbolizes the commitment of brilliant health specialists at the service of NASH patients, as shown by Professors Francque’s and Cariou’s involvement in the Scientific Committee. It will give us the opportunity to explain how **The NASH Education Program™** is intending to provide concrete and pragmatic answers to the large unmet needs that exist today when it comes to scientific and medical knowledge around NASH and its related challenges. It will also be the occasion to provide a global picture about the first initiatives engaged or planned by **The NASH Education Program™** in this direction as early as 2017. As a leader in the development of diagnostic and therapeutic solutions for NASH, one of GENFIT’s responsibilities is also to drive actions related to healthcare education. The level of interest demonstrated since we first announced this initiative reinforces our belief that collaborative approaches are a good way to move forward in the field.”*

ABOUT NASH

“NASH”, or nonalcoholic steatohepatitis, is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. The disease is associated with long term risk of progression to cirrhosis, a state where liver function is diminished, leading to liver insufficiency, and also progression to liver cancer.

ABOUT THE NASH EDUCATION PROGRAM™

The Nash Education Program™ is an endowment fund created end of 2016 by GENFIT, with the objective to develop disease awareness initiatives around NASH, and as such address unmet information needs across a large set of stakeholders in the disease. Its investments should allow the fund to play an active educational role in the acquisition, production and dissemination of medical and scientific knowledge, towards the medical community, patients, and general public, under the supervision of a scientific committee.

[Visit our website](#)

CONTACT

PRESS RELATIONS | Bruno Arabian | +33 (0)6 8788 4726